Advertisement

Related Videos

Daniel Goldstein, MD: Interventional Pharmacoeconomics - Why and How

Peter Clark, MA, MD, FRCP: A Payer Perspective

Cody Peer, PhD, on Simulating Alternative Schedules for Checkpoint Inhibitors

Mark Sculpher, PhD: How Do We Assess the Value of Cancer Drug Optimization?

Amit Sanyal, MD: A Clinician’s Perspective

Advertisement

Advertisement




Oct
08
Today In Oncology
HER2-Positive Breast Cancer FDA Approves Triplet for Maintenance Therapy
GLP-1 Receptor Agonist Use Linked to Lower Colorectal Cancer Risk in Patients With Inflammatory Bowel Disease
Pediatric Bone Sarcoma Gets First NCCN Guidelines
2026 Albany Prize Awardees Announced
ACS Study Quantifies Financial Burden of Cancer in Older Patients
View More 
Advertisement
© 2026 HSP News Service, L.L.C.
Conexiant Oncology Logo